Journal of Medicine and Palliative Care (JOMPAC) is an open access scientific journal with independent, unbiased, and double-blind review under international guidelines. The purpose of JOMPAC is to contribute to the literature by publishing articles on health sciences and medicine.

EndNote Style
Original Article
Evaluation of clopidogrel use on gastric precancerous lesions: does it have chemopreventive effect?
Aims: Gastric malignancies are the third most common cause of cancer-related deaths. Although aspirin and clopidogrel have been reported to reduce the risk of colorectal cancer, their effects on gastric cancer are still under investigation. In this study, we aimed to determine whether clopidogrel has an effect on the development of gastric precancerous lesions.
Methods: The study was designed as a retrospective case-control study. The study was conducted between January 2021 and April 2023 in the Gastroenterology Clinic of Samsun Training and Research Hospital. Patients who underwent upper GIS endoscopy and biopsy examination due to dyspeptic complaints were scanned from the electronic data system of the hospital and their data were recorded by forming 4 groups as clopidogrel (89 patients), low-dose aspirin (ASA) (172 patients), non-aspirin non-steroidal anti-inflammatory drug (NA-NSAID) users (110 patients) and control group without antiplatelet use (110 patients).
Results: Mean duration of drug use was 2 years for clopidogrel, 1.47 years for ASA and 0.35 years for NA-NSAID. The incidence of peptic ulcer was 7.2% in the control group, 38%, 15.1%, 49% in clopidogrel, ASA, NA-NSAID users, respectively (p<0.001). The frequencies of H. pylori infection in the groups were 61%, 53.5%, 40.1%, 46.1%, respectively. There was a significant difference between ASA and control group (p<0.001). Intestinal metaplasia was observed in 23.1%, 29.5%, 31.2%, 23.1%, respectively (p=0.291). Atrophic gastritis was seen in 16.6%, 35.2%, 19.2%, 29.3%, respectively (p=0.003). No difference was observed between the groups in terms of dysplasia, gastric cancer and esophageal cancer.
Conclusion: According to our results, no preventive effects of clopidogrel, ASA and NA-NSAID use on precancerous lesions or gastric cancer development were observed. However, the use of these drugs was associated with severe gastroduodenal lesions.

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A.Global cancer statistics 2018: GLOBOCAN estimates of incidenceand mortality worldwide for 36 cancers in 185 countries. CACancer J Clin. 2018;68(6):394-424.
2. Demirci H, Ozturk K, Tanoglu A, et al. Helicobacter pyloricolonization density is an important risk factor for eradicationtherapy. J Gastrointestin Liver Dis. 2022;31(2):163-167.
3. Kaplan M, Tanoglu A, Duzenli T, Tozun AN. Helicobacterpylori treatment in Turkey: current status and rational treatmentoptions. North Clin Istanb. 2019;7(1):87-94.
4. Kalkanlı Taş S, Kırkık D, &Ouml;zt&uuml;rk K, Tanoğlu A. Determinationof B- and T- cell epitopes for Helicobacter pylori cagPAI: An insilico approach. Turk J Gastroenterol. 2020;31(10):713-720.
5. Ford AC, Yuan Y, Moayyedi P. Helicobacter pylori eradicationtherapy to prevent gastric cancer: systematic review and meta-analysis. Gut. 2020;69(12):2113-2121.
6. Algra AM, Rothwell PM. Efects of regular aspirin on long termcancer incidence and metastasis: a systematic comparison ofevidence from observational studies versus randomised trials.Lancet Oncol. 2012;13(5):518-527.
7. Kim YL, Kim SY, Kim KJ, et al. Long-term low-dose aspirin usereduces gastric cancer incidence: a nationwide cohort study.Cancer Res Treat. 2016;48(2):798-805.
8. Bofei Li, Cheung KS, Wong IY, et al. Nonaspirin nonsteroidalanti-inflammatory drugs and gastric cancer risk afterHelicobacter pylori eradication: a territory-wide study. Cancer.2021;127(11):1805-1815.
9. Miguel RA, Luis A, Rodr&iacute;guez GI, et al. Clopidogrel and low-doseaspirin, alone or together, reduce risk of colorectal cancer. ClinGastroenterol Hepatol. 2019;17(10):2024-2033.
10. Tsai TJ, Lai KH, Hsu PI, et al. Upper gastrointestinal lesions inpatients receiving clopidogrel anti-platelet therapy. J Formos MedAssoc. 2012;111(12):705-710.
11. Fork FT, Lafolie P, Toth E, Lindgarde F. Gastroduodenal toleranceof 75 mg clopidogrel versus 325 mg aspirin in healthy volunteers.A gastroscopic study. Scand J Gastroenterol. 2000;35(5):464-469.
12. Lanza FL. A review of gastric ulcer and gastroduodenal injury innormal volunteers receiving aspirin and other non-steroidal anti-inflammatory drugs. Scand J Gastroenterol Suppl. 1989;163:24-31.
13. Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirinand esomeprazole to prevent recurrent ulcer bleeding. N Engl JMed. 2005;352(3):238-244.
14. Sinha M, Gautam L, Shukla PK, et al. Current perspectivesin NSAID-induced gastropathy. Mediators Inflamm.2013;2013:258209.
15. Wang D, Dubois RN. Prostaglandins and cancer. Gut.2006;55(1):115-122.
16. Cheung KS, Chan EW, Wong AYS, et al. Aspirin and risk ofgastric cancer after Helicobacter pylori eradication: a territory-wide study. J Natl Cancer Inst. 2018;110(7):743-749.
17. Weltermann T, Schulz C, Macke L. Effect of frequently prescribeddrugs on gastric cancer risk. Best Pract Res Clin Gastroenterol.2021;50-51:101741.
18. Altayar O, Davitkov P, Shailja C, et al. AGA Technical reviewon gastric intestinal metaplasia - epidemiology and risk factors.Gastroenterology. 2020;158(3):732-744.
19. Song H, Ekheden IG, Zheng z, et al. Incidence of gastriccancer among patients with gastric precancerous lesions:observational cohort study in a low risk Western population. BMJ2015;351:3867.
20. Sonnenberg A, Genta RM. Changes in the gastric mucosa withaging. Clin Gastroenterol Hepatol. 2015;13(13):2276-22781.
21. Ozdil K, Sahin A, Kahraman R, et al. Current prevalence ofintestinal metaplasia and Helicobacter pylori infection indyspeptic adult patients from Turkey. Hepatogastroenterology.2010;57(104):1563-1566.
22. Kiyak M, Duzenli T. Helicobacter pylori colonization densitymay have an important role in the development of celiac disease.Turk J Acad Gastroenterol. 2023;22(1):6-12.
23. Nagata N, Niikura R, Sekine K, et al. Risk of peptic ulcer bleedingassociated with Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs, low-dose aspirin, and antihypertensivedrugs: a case-control study. J Gastroenterol Hepatol.2015;30(2):292-298.
24. K&ouml;seoğlu H, Duzenli T, Sezikli M. Gastric neuroendocrineneoplasms: a review. World J Clin Cases. 2021;9(27):7973-7985.
25. Annibale B, Esposito G, Lahner E. A current clinical overviewof atrophic gastritis. Expert Rev Gastroenterol Hepatol.2020;14(2):93-102.
26. Clemens A, Strack A, Noack H. Anticoagulant-relatedgastrointestinal bleeding&mdash;could this facilitate early detectionof benign or malignant gastrointestinal lesions? Ann Med.2014;46(8):672-678.
27. Dixon MF, Genta RM, Yardley JH, Correa P. Classification andgrading of gastritis. The updated Sydney System. InternationalWorkshop on the Histopathology of Gastritis, Houston 1994. AmJ Surg Pathol. 1996;20(10):1161-1181.
Volume 4, Issue 5, 2023
Page : 524-529